Exposure-Response Analysis of Necitumumab Efficacy in Squamous Non-Small Cell Lung Cancer Patients.

about

Exposure-Response Analysis of Necitumumab Efficacy in Squamous Non-Small Cell Lung Cancer Patients.

Item

http://www.wikidata.org/entity/Q41526288

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Exposure-Response Analysis of ...... all Cell Lung Cancer Patients.

@en

type

Item

label

Exposure-Response Analysis of ...... all Cell Lung Cancer Patients.

@en

prefLabel

Exposure-Response Analysis of ...... all Cell Lung Cancer Patients.

@en

P1476

Exposure-Response Analysis of ...... all Cell Lung Cancer Patients.

@en

P2093

A J Long

http://www.w3.org/2001/XMLSchema#string

E Chigutsa

http://www.w3.org/2001/XMLSchema#string

J E Wallin

http://www.w3.org/2001/XMLSchema#string

P2860

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

A Review of Modeling Approaches to Predict Drug Response in Clinical Oncology

Nondermatologic adverse events associated with anti-EGFR therapy.

Nonlinear pharmacokinetics of therapeutic proteins resulting from receptor mediated endocytosis

Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria.

A phase I pharmacologic study of necitumumab (IMC-11F8), a fully human IgG1 monoclonal antibody directed against EGFR in patients with advanced solid malignancies.

Necitumumab, a fully human IgG1 mAb directed against the EGFR for the potential treatment of cancer.

Population pharmacokinetic-pharmacodynamic modelling in oncology: a tool for predicting clinical response.

Anti-EGFR therapies: clinical experience in colorectal, lung, and head and neck cancers.

PKPD Modeling of Predictors for Adverse Effects and Overall Survival in Sunitinib-Treated Patients With GIST.

P304

560-568

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/PSP4.12209

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-05-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28569042

http://www.w3.org/2001/XMLSchema#string

P932

5572351

http://www.w3.org/2001/XMLSchema#string

Exposure-Response Analysis of Necitumumab Efficacy in Squamous Non-Small Cell Lung Cancer Patients.

about

Exposure-Response Analysis of Necitumumab Efficacy in Squamous Non-Small Cell Lung Cancer Patients.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P932